Sarepta Therapeutics (SRPT) News
NASDAQ: SRPTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
13.33-0.84 (-5.93%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SRPT news summary
We found 5 recent headlines mentioning Sarepta Therapeutics (SRPT): 0 in the past week and 4 in the past 30 days, most often from Nasdaq, Business Wire, Seeking Alpha. SRPT is making an outsized move today, down 5.93% at $13.33, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Sarepta (SRPT) Q3 2026 Earnings Call Transcript", was published by Nasdaq on Nov 6, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Sarepta Therapeutics headlines
- Sarepta (SRPT) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales DeclineSarepta's mixed Q3 results send shares down, as earnings miss and weaker Elevidys sales weigh on investor sentiment.NasdaqSRPT, AMRX, IBRX
- Sarepta Therapeutics Non-GAAP EPS of $0.13 misses by $0.23, revenue of $381.3M beats by $31.2MSeeking Alpha
- Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate DevelopmentsCAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of…Business Wire
- Sarepta Therapeutics to Announce Third Quarter 2026 Financial ResultsCAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2026 financial results after the…Business Wire